Review
Copyright ©The Author(s) 2015.
World J Clin Cases. Jul 16, 2015; 3(7): 545-555
Published online Jul 16, 2015. doi: 10.12998/wjcc.v3.i7.545
Table 1 Main characteristics of available disease-modifying therapies for multiple sclerosis
AgentIndication and line of therapyDosage, route and frequencyClinical efficacy in placebo-controlled phase III trialsTolerability issuesSafety issues
Interferon beta 1bRR MS; SP MS with relapses; CIS First line250 mcg s.c. every other day34% reduction of ARR over two years (RR MS) 50% risk reduction of conversion to CD MS at two years (CIS) No statistically significant effect on disability progressionFlu-like syndrome; injection site reactionsHepatotoxicity; myelotoxicity; autoimmune thyroiditis; microangiopathy; epileptic seizures (rare)
Interferon beta 1aRR MS; CIS First line30 mcg i.m. once a week18% reduction of ARR over two years (RR MS) 44% risk reduction of conversion to CD MS at two years (CIS) No statistically significant effect on disability progressionSame as aboveSame as above
Interferon beta 1aRR MS; CIS First line44 mcg s.c. three times a week32% reduction of ARR over two years (RR MS) 45% risk reduction of conversion to CD MS at two years (CIS) 30% reduction of progression of disability at two years (RR MS)Same as aboveSame as above
Peginterferon beta 1aRR MS First line125 mcg s.c. every two weeks36% reduction of ARR over one yearSame as aboveSame as above
Glatiramer acetateRR MS; CIS First line20 mg s.c. every day29% reduction of ARR over two years (RRMS) 45% risk reduction of conversion to CDMS at three years (CIS) No statistically significant effect on disability progressionInjection site reactions; post-injection reaction (chest pain, flushing and dyspnea)Cutaneous necrosis; anaphylaxis (rare)
MitoxantroneRR MS; SP MS; PR MS Second or third line12 mg/m2i.v. every three months or 8 mg/m2i.v. every month65% reduction of relapse risk over two years (mostly in RR MS)[98] 66% reduction of risk of disability progression at two years (mostly in RR MS)[98]Nausea/vomiting; amenorrhea/infertility; alopecia; blue discoloration of sclera and urineInfusion site tissue necrosis; myelotoxicity; infections; cardiotoxicity; acute leukemia
NatalizumabRR MS Second line300 mg i.v. every four weeks68% reduction of ARR over two years 42% reduction of progression of disability at two yearsHeadacheInfusion associated reactions; anaphylaxis; infections; hepatotoxicity; progressive multifocal leukoencephalopathy
FingolimodRR MS Second line (first line in the United States)0.5 mg per os every day48%-54% reduction of ARR over two years 30% reduction of progression of disability at two yearsFatigue; headacheBradyarrhythmias after first dose; lymphopenia; viral infections (VZV); macular edema; hepatotoxicity; hypertension
TeriflunomideRR MS First line14 mg per os every day31%-36% reduction of ARR over one year or more 26%-32% reduction of progression of disability at one year or moreNausea; diarrhea; alopeciaMyelotoxicity; hepatotoxicity; infections; peripheral neuropathy; pancreatic fibrosis; teratogenicity (requires accelerated elimination procedure)
Dimethyl fumarateRR MS First line240 mg per os twice a day44%-53% reduction of ARR over two years 38% reduction of progression of disability at two yearsFlushing; gastrointestinal symptoms; pruritusLymphopenia; progressive multifocal leukoencephalopathy
AlemtuzumabRR MS Second or third line12 mg/d i.v. for five days followed by 12 mg/d i.v. for three days one year after the first course49%-55% reduction of ARR over two years compared to s.c. interferon beta 1a 42% reduction of progression of disability at two years compared to s.c. interferon beta 1aInfusion associated reactions; myalgia; arthralgia; irregular menstruationInfusion associated reactions; cytokine release syndrome; lymphopenia; infections; autoimmune thyroiditis; thrombocytopenic purpura; glomerulonephritis
Azathioprine1MS of all types First or second line2.5 mg/kg per os every day23% relative risk reduction of the frequency of relapses over two years No statistically significant effect on disability progression at two and three years[98]Gastrointestinal symptoms; photosensitivity; irregular menstruation/reduced fertilityMyelotoxicity; hepatotoxicity; lymphopenia; infections; acute pancreatitis; increased toxicity in subjects with thiopurine methyltransferase deficiency; malignancies (cumulative dose > 600 g)
Cyclophos- phamide1SP MS; PP MS Third line1 g i.v. over three days or 500 mg i.v. over five daysNo statistically significant effect on disability progression at two and three years[98]Nausea/vomiting; amenorrhea/infertility; alopeciaMyelotoxicity; hepatotoxicity; infections; hemorrhagic cystitis; bladder cancer